Research:​

There is a significant amount of clinical research, taking place around Scotland, relating to interventional cardiology. SICNAP hopes to highlight some of these studies, during the recruitment phase, and also report back on the conclusions and findings following the completion and analysis of the data.

​

If you are involved in clinical research and would like to share with SICNAP members, contact us at sicnap@mail.com and we will highlight your work

​UK Multi-Centre developmental clinical study of management guided by coronary angiography combined with fractional flow reserve (FFR) measurement versus management guided by coronary angiography alone (standard care) in patients with non-ST elevation MI.

Do treatment decisions correspond to FFR values in individual coronary arteries in patients with recent NSTEMI

 

Data analysis in progress, findings and conclusion ​in due course.

​

​

http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11254

​

​The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation Myocardial Infarction (STEMI).

After acute myocardial infarction and successful stent implantation patients will undergo a baseline MRI (magnetic resonance imaging) for eligibility for the study. Patients will receive POL6326 or placebo in the first week after STEMI.

 

Recruiting at both Golden Jubilee National Hospital & Royal Infirmary of Edinburgh

​

http://clinicaltrials.gov/ct2/show/NCT01905475

​

The purpose of LEADERS FREE is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and definite/probable stent thrombosis, and that its efficacy is superior to a bare metal stent as measured by clinically driven TLR at one year.

​

Any indication for PCI in patients deemed at high risk for bleeding and candidates for 1 month DAPT. This includes candidates with stable angina, silent ischemia, ACS (STEMI and non-STEMI), non-native lesions and in-stent restenosis.

​

http://clinicaltrials.gov/show/NCT01623180

The theory behind the study is that stenting of the left main stem may be of equal efficacy and safety to the current gold standard treatment, which is coronary artery bypass surgery.

​

​The purpose of the study is to find the most effective treatment for unprotected left main stenosis (UPLM) disease. The patients will be randomised after the diagnostic angiogram and when both the cardiac surgeons and interventional cardiologists have agreed the patient is suitable for either treatment group.

​

A registry of all UPLM patients and reasons for inclusion and exclusion will be also documented during the study.

​

​

http://www.controlled-trials.com/ISRCTN87206264